ArticleEuropean journal of clinical nutrition2019
Update of the European consensus on sarcopenia: what has changed in diagnosis and prevalence in peritoneal dialysis?
Article in European journal of clinical nutrition, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 17 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 2 syntheses or guidelines pooled it, 31 citations in OpenAlex.
- Diagnosis, prevalence, and mortality of sarcopenia in dialysis patients: a systematic review and meta-analysis.Journal of cachexia, sarcopenia and muscle · 2022Pooled it
- Prevalence and Risk Factors of Sarcopenia in People Receiving Dialysis: A Systematic Review and Meta-Analysis.Seminars in dialysisPooled it
- Efficacy of Transcatheter Renal Arterial Embolization to Contract Renal Size and Increase Muscle Mass in Patients with Polycystic Kidney Disease.Diagnostics (Basel, Switzerland) · 2026Article
- Recent Sarcopenia Definitions-Variability in Prevalence and Disability Associations in Peritoneal Dialysis Patients.Journal of cachexia, sarcopenia and muscle · 2025Article
- Depression as a risk factor for osteoporosis independent of sarcopenia in hemodialysis patients: findings from a multicenter cross-sectional study.BMC nephrology · 2025Article
- Pharmacologic therapeutics in sarcopenia with chronic kidney disease.Kidney research and clinical practice · 2024Article
- Association between sarcopenic obesity and mortality in patients on peritoneal dialysis: a prospective cohort study.Frontiers in medicine · 2024Article
- Sarcopenia in chronic kidney disease: from bench to bedside.The Korean journal of internal medicine · 2023Review
- Sarcopenia in Chronic Kidney Disease: A Scoping Review of Prevalence, Risk Factors, Association with Outcomes, and Treatment.Calcified tissue international · 2022Article
- Current status of the assessment of sarcopenia, frailty, physical performance and functional status in chronic kidney disease patients.Current opinion in nephrology and hypertension · 2022Review
- The combination of phase angle and age has a good diagnostic value for sarcopenia in continuous ambulatory peritoneal dialysis patients.Frontiers in nutrition · 2022Article
- Sarcopenia in chronic kidney disease: what have we learned so far?Journal of nephrology · 2021Review
- Age, diabetes mellitus, and dialysis modality are associated with risk of poor muscle strength and physical function in hemodialysis and peritoneal dialysis patients.Kidney research and clinical practice · 2021Article
- Association Between Phase Angle and Sarcopenia in Patients Undergoing Peritoneal Dialysis.Frontiers in nutrition · 2021Article
- Association of Phase Angle, but Not Inflammation and Overhydration, With Physical Function in Peritoneal Dialysis Patients.Frontiers in nutrition · 2021Article
- Article
- Sarcopenia and Liver Cirrhosis-Comparison of the European Working Group on Sarcopenia Criteria 2010 and 2019.Nutrients · 2020Article
Corrections and comments
- Erratum issued
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Patients on peritoneal dialysis (PD) may be affected by sarcopenia, which is a progressive and generalized skeletal muscle disorder characterized by muscle mass atrophy with decline of muscle strength and function. The aim was to evaluate differences in the diagnosis and prevalence of sarcopenia according to European Working Group on Sarcopenia in Older People (EWGSOP). The screening for sarcopenia was performed in PD patients older than 18 years, with evaluation of appendicular skeletal muscle mass index (ASMMI), handgrip strength (HGS) and gait speed (GS). The diagnosis was according to the 2010 and 2019 versions of EWGSOP consensus on sarcopenia. Fifty subjects on PD were included, mean age 55.74 ± 16.22 years old, 52% female. The prevalence of sarcopenia ranged from 4 to 10% according to cut points and references used.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.